Alpha 2.0
Login Register
» Articles » PMID: 35678591

Treatment of COVID-19-induced Refractory Status Epilepticus by Tocilizumab

Overview
Journal Eur J Neurol
Publisher Wiley
Specialty Neurology
Date 2022 Jun 9
PMID 35678591
Authors
Esra Kochan Kizilkilic
Rumeysa Unkun
Ugur Uygunoglu
Sakir Delil
Cigdem Ozkara
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: COVID-19 is a novel infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in which neurological complications have been increasingly recognized. Acute symptomatic epileptic seizures and status epilepticus are frequently reported neurological complications associated with this infection. The nervous system damage caused by SARS-CoV-2 may be mediated by the immune system. Interleukin 6 (IL-6), an important component of the cytokine storm, is directly correlated with the severity of symptoms. Tocilizumab is an inhibitor of IL-6 receptors, which blocks IL-6-mediated signal transduction and is used in the treatment of COVID-19 and status epilepticus.

Case Report: A patient with the Unverricht-Lundborg disease is presented who had developed refractory recurrent status epilepticus during COVID-19 infection, which was finally controlled by treatment with tocilizumab.

Discussion: Tocilizumab, an IL-6 inhibitor, may be considered as a treatment option in patients with status epilepticus and refractory seizures.

Citing Articles

Intrathecal tocilizumab for immune-mediated central nervous system complication after haploidentical hematopoietic stem cell transplantation in children: Two case reports.

Gui R, Li Z, Wang J, Zu Y, Zhang B, Zhao J Heliyon. 2024; 10(22):e40356.

PMID: 39624308 PMC: 11609442. DOI: 10.1016/j.heliyon.2024.e40356.

The Contribution of Microglia and Brain-Infiltrating Macrophages to the Pathogenesis of Neuroinflammatory and Neurodegenerative Diseases during TMEV Infection of the Central Nervous System.

DePaula-Silva A Viruses. 2024; 16(1).

PMID: 38257819 PMC: 10819099. DOI: 10.3390/v16010119.

Neuroinflammation and status epilepticus: a narrative review unraveling a complex interplay.

Foiadelli T, Santangelo A, Costagliola G, Costa E, Scacciati M, Riva A Front Pediatr. 2023; 11:1251914.

PMID: 38078329 PMC: 10703175. DOI: 10.3389/fped.2023.1251914.

SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19.

Liang H, Wu Y, Yau V, Yin H, Lowe S, Bentley R Vaccines (Basel). 2022; 10(9).

PMID: 36146616 PMC: 9504858. DOI: 10.3390/vaccines10091538.

Frequency of new seizures after SARS-CoV-2 infections may depend on the length of follow-up.

Finsterer J Seizure. 2022; 104:43-44.

PMID: 35965222 PMC: 9359591. DOI: 10.1016/j.seizure.2022.08.001.

References
1.
Carroll E, Neumann H, Aguero-Rosenfeld M, Lighter J, Czeisler B, Melmed K . Post-COVID-19 inflammatory syndrome manifesting as refractory status epilepticus. Epilepsia. 2020; 61(10):e135-e139. PMC: 7537028. DOI: 10.1111/epi.16683. View
2.
Kashyap H, Gupta V, Gupta A, Gupta T, Sharma S, Valjiyani S . Post-COVID Syndrome (MIS-C) with Refractory Status Epilepticus. Indian J Pediatr. 2021; 88(7):721. PMC: 8057941. DOI: 10.1007/s12098-021-03731-7. View
3.
Anwar M . Immunotherapies and COVID-19 related Neurological manifestations: A Comprehensive Review Article. J Immunoassay Immunochem. 2021; 41(6):960-975. DOI: 10.1080/15321819.2020.1865400. View
4.
Dono F, Nucera B, Lanzone J, Evangelista G, Rinaldi F, Speranza R . Status epilepticus and COVID-19: A systematic review. Epilepsy Behav. 2021; 118:107887. PMC: 7968345. DOI: 10.1016/j.yebeh.2021.107887. View
5.
Emami A, Fadakar N, Akbari A, Lotfi M, Farazdaghi M, Javanmardi F . Seizure in patients with COVID-19. Neurol Sci. 2020; 41(11):3057-3061. PMC: 7501768. DOI: 10.1007/s10072-020-04731-9. View